Background & relevance

The optimal treatment choice/sequence for an individual patient with castration-resistant prostate cancer (CRPC) is challenging. This topic is limited to patients with a castrate testosterone level. Bone-protective agents fall beyond the scope of this topic.

Regulatory approval status of drugs for CRPC discussed in this topic (indications limited to the CRPC setting)